Related Experiment Videos
Rethinking Lipid Burden and the Role of Non-LDL Biomarkers in Stroke Risk Stratification
Sean Michael Kelly1,2,3, Julia Schneider4,5,6, Michela Rosso4,5,6
1New York University Grossman School of Medicine, New York, United States. sean.kelly2@nyulangone.org.
Insights
Non-low-density lipoprotein-cholesterol (LDL-C) biomarkers improve atherosclerotic cardiovascular disease risk assessment. Additional lipid measures like triglyceride-to-high density lipoprotein ratio (TG:HDL), lipoprotein (a) (Lp(a)), and apolipoprotein B (ApoB) aid in stroke risk stratification and secondary prevention.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Neurology
Background:
- Established link between elevated low-density lipoprotein-cholesterol (LDL-C) and atherosclerosis.
- Growing evidence suggests non-LDL-C biomarkers offer more precise cardiovascular disease (CVD) risk stratification.
Purpose of the Study:
- Review literature on non-LDL biomarkers in atherosclerotic cardiovascular disease (ACSVD).
- Examine their role in atherogenesis and ischemic stroke risk.
- Discuss future applications in secondary stroke prevention.
Main Methods:
- Literature review of existing studies on non-LDL biomarkers.
- Analysis of lipid panel components and additional lipoprotein assays.
- Evaluation of their association with atherosclerosis and stroke risk.
Main Results:
- Non-traditional markers, beyond LDL-C, refine CVD risk assessment.
- Measures like triglyceride-to-high density lipoprotein ratio (TG:HDL), lipoprotein (a) (Lp(a)), and apolipoprotein B (ApoB) are important.
- These markers help estimate metabolic health and atherogenic particle burden.
Conclusions:
- Non-LDL biomarkers are crucial for comprehensive stroke risk assessment.
- Consideration of TG:HDL, Lp(a), and ApoB is recommended for monitoring and secondary stroke prevention.
- Further research is needed to fully define their role in ischemic stroke risk.
Purpose Of Review:
This article reviews the existing literature on non-LDL biomarkers in atherosclerotic cardiovascular disease (ACSVD), atherogenesis, and ischemic stroke risk, including a discussion of potential future applications for secondary prevention of stroke.
Recent Findings:
Although foundational studies established the strong link between elevated low-density lipoprotein-cholesterol (LDL-C) with the development of atherosclerosis and increased cardiovascular risk, a growing number of recent studies have shown that more precise cerebrovascular disease (CVD) risk stratification can be achieved by using other components of the traditional lipid panel along with additional lipoprotein assays. The specific relationship between these non-traditional markers of atherosclerosis and ischemic stroke risk remains incompletely defined. Lipid measures beyond LDL-C including updated interpretations of the standard lipid panel, such as the triglyceride-to-high density lipoprotein ratio (TG:HDL) as well as testing for lipoprotein (a) (Lp(a)) and apolipoprotein B (ApoB), play a important respective roles in estimating metabolic health as well as atherogenic particle burden. These measures should therefore be considered in the context of stroke risk assessment, monitoring, and secondary prevention.
Related Concept Videos
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease I: Introduction
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT